The maintenance of the protein quality control pathways in the
cell is essential to human health. At Proteostasis Therapeutics, we
have discovered new groundbreaking therapies to treat cystic
fibrosis, a disease caused by the dysfunctional CFTR protein. Three novel CFTR modulators are being investigated in clinical trials in CF
patients. We also have a collaboration with Astellas Pharma Inc. to
research and identify therapies targeting the Unfolded Protein Response (UPR) pathway.